Hensoldt Q3 adjusted EBITDA beats forecasts, 2026 sales target raised

Hensoldt’s Q3 adjusted EBITDA rose to €144 million from €104 million a year earlier, beating expectations by 12%; revenue of €696 million was 2% above consensus, and the adjusted EBITDA margin expanded to 20.6% from 17.6%. The company raised its 2026 revenue target to about €2.80 billion, still roughly 1% below consensus, and lifted the lower end of its margin range to about 19%. Nine-month orders climbed 76.7% to €3.56 billion and backlog reached a record €10.37 billion, while Q3 free cash flow of about €32 million fell short of €38 million consensus; Jefferies described the revenue outlook as conservative.

Analysis

The key tension is earnings quality versus delivery: stronger margins and a deep order book support the medium-term case, but the 2026 revenue guide remains below expectations and the implied EBITDA/FCF are not clear estimate-raisers. That makes this more an execution story than an obvious post-beat re-rating. The removal of pass-through revenue guidance also makes headline sales comparisons less informative; investors should focus on organic delivery, margin mix and cash conversion.

Over 1–3 months, the London capital-markets day is the catalyst to test whether production ramp-up can convert backlog into revenue without eroding margins or tying up more working capital. Orders are not cash: recent FCF benefited from customer advances, so a slowdown in advance payments or delayed acceptance could expose a gap between reported EBITDA and cash generation. PEGASUS appears less immediately binary if the order outlook holds without an award; a delay would chiefly defer upside rather than invalidate the base case. Over 6–18 months, sustained procurement demand benefits Hensoldt, while electronics-component capacity and delivery bottlenecks could constrain conversion and give diversified peers such as Thales, Saab and Leonardo an advantage if customers seek alternate capacity.

Contrarian angle: a large backlog can be mistaken for near-term earnings visibility. The market may be underpricing working-capital and execution risk even as it focuses on the EBITDA beat. Conversely, if CMD commentary validates delivery cadence and cash conversion, conservative revenue guidance could leave room for estimates to move up. The thesis weakens if margin guidance is cut, order conversion slips, or FCF misses despite continued customer advances.

Key Decisions for Investors

• Do not chase the EBITDA beat alone. Keep HAG on a catalyst watchlist and consider a staged long only after the capital-markets day confirms production cadence, margin durability and a credible path to cash conversion.
• For an existing long, size around the cash-flow risk: reduce or hedge if HAG’s FCF trajectory deteriorates while EBITDA remains strong, since that would indicate backlog is not converting cleanly into cash.
• Track quarterly organic revenue, book-to-bill, adjusted FCF and customer-advance receipts separately; verify whether the lower revenue outlook reflects mix/pass-through changes or weaker underlying deliveries before revising estimates.
• Falsifiers: a margin-range reduction, persistent FCF shortfalls versus the roughly 50% conversion ambition, or evidence that major contract deliveries are slipping. A timely PEGASUS award is upside optionality, not a necessary condition for the base thesis.